

Nutritional Status, Bioactive Properties, & Therapeutic Efficacy of Omega-3 Polyunsaturated Fatty Acids Obtained by Green-Synthetic Routes

Mukesh Chander*

Abstract

*Polyunsaturated fatty acids (PUFAs), particularly omega-3 (n-3) fatty acids, like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are crucial for human health. They support structural brain development, visual acuity, and cardiovascular function, while also exhibiting potent anti-inflammatory, antioxidant, and antimicrobial properties. Historically, marine fish oil has been the primary dietary source of these essential fatty acids. However, escalating concerns regarding ecological environmental impacts, the oceanic bioaccumulation of heavy metal contaminants, and the fundamental limits of global supply have spurred immense interest in the microbial production of PUFAs as a sustainable, land-based, and cost-effective alternative. This review synthesizes current knowledge on the nutritional, therapeutical and biological importance of omega-3 fatty acids and explores the distinct advantages of their microbial biosynthesis. We thoroughly examine the cellular mechanisms of oleaginous microorganisms, including marine microalgae, thraustochytrids, filamentous fungi (such as *Mortierella* species), and robust yeasts like *Yarrowia lipolytica*. Furthermore, recent breakthroughs in metabolic engineering and genetic manipulation, specifically the targeted overexpression of desaturase and elongase enzymes to overcome native lipid biosynthetic bottlenecks, have been critically assessed. Crucially, the integration of advanced bioprocess engineering to scale up single-cell oil production through the valorization of agro-industrial and horticultural wastes has been reviewed based on post 2010 scientific data and research papers. Implementing abundant, low-cost substrates, such as sugarcane molasses, corn steep liquor, and fruit processing residues, not only substantially reduces fermentation costs but actively promotes a circular agricultural bioeconomy. We detail fermentation optimization strategies tailored to these complex carbon sources to maximize intracellular lipid accumulation. Finally, while discussing the safety and economic aspects of microbial PUFAs, this review outlines downstream processing metrics and provides a strategic roadmap for translating these vital biotechnological advances into commercial-scale, sustainable production and a potent therapeutic and nutritional source.*

Keywords: Anti-inflammatory, antimicrobial, antioxidant, docosahexanoic acid, eicosapentaenoic acid, green synthesis, polyunsaturated fatty acids

*Author for Correspondence

Mukesh Chander

E-mail: mukeshchander76@yahoo.co.in

Assistant Professor & Dean Research (Former), Department of Biotechnology, Bioprocess Laboratory, P.G., Khalsa College (Autonomous), Amritsar, Punjab, India

Received Date: May 19, 2026

Accepted Date: May 28, 2026

Published Date: May 30, 2026

Citation: Mukesh Chander. Nutritional Status, Bioactive Properties, & Therapeutic Efficacy of Omega-3 Polyunsaturated Fatty Acids Obtained by Green-Synthetic Routes. International Journal of Nutritions. 2026; 3(2): 47–65p.

INTRODUCTION

Fatty acids (FAs) are fundamental lipids characterized by a hydrocarbon chain and a carboxyl group, classified based on the presence and number of double bonds into saturated [1–4], monounsaturated (MUFAs), and polyunsaturated (PUFAs) [5, 6]. While saturated and MUFAs can be synthesized by the human body [7], PUFAs are considered essential fatty acids (EFAs) that must be obtained through diet [8]. The two most significant families of PUFAs are omega-6 (n-6) and omega-3 (n-3) [9]. Maintaining an optimal nutritional status

of these crucial lipids is foundational for human health [5], yet the modern Western diet often presents a significant challenge due to a disproportionately high n-6 to n-3 ratio, frequently leading to a suboptimal cellular lipid profile [10, 11]. Key n-3 PUFAs include alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Due to the human body's limited conversion of ALA to EPA and DHA, direct dietary intake of these longer-chain n-3 FAs is crucial [12–19]. Although ALA is relatively abundant in terrestrial plant sources, like flaxseed and chia, human metabolic pathways relying on alternating desaturases and elongases to convert ALA to longer forms are remarkably inefficient and broadly considered inadequate from a medical standpoint [16]. Consequently, securing a robust physiological nutritional status directly relies on the reliable dietary intake of pre-formed EPA and DHA [7, 20–27].

The profound physiological impact of these lipids is fundamentally rooted in their unique bioactive properties and structural mechanisms [24]. Structurally, EPA possesses 20 carbons and five double bonds, whereas DHA contains 22 carbons and six double bonds (Figure 1). Once consumed, these long-chain PUFAs are rapidly esterified and seamlessly integrated into the cellular phospholipid bilayer [23]. This cellular insertion is highly biologically active; the multiple cis-double bonds characteristic of n-3 PUFAs [28–31] introduce distinct structural kinks that significantly enhance membrane fluidity, alter lipid raft dynamics, and profoundly influence cross-membrane signal transduction [32, 33]. By decreasing cholesterol accumulation within the cellular membrane, they optimize the function of embedded protein receptors [34, 35]. Furthermore, EPA and DHA function as indispensable bioactive precursors for specialized pro-resolving mediators (SPMs) [36–44]. These potent autacoids actively orchestrate the resolution phase of cellular inflammation, effectively clearing cellular debris and restoring tissue homeostasis without suppressing necessary host immune defenses [3, 9, 10]. The antiallergic and neuroprotective effects of microbial PUFA have been reported in developing children [1, 2, 5, 11–18].




Figure 1. Molecular structure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Translating these cellular dynamics into clinical outcomes reveals the vast therapeutic efficacy of EPA and DHA across a multitude of human organ systems [1, 4, 7, 13, 19, 20]. From a cardiovascular perspective [21], routine dietary intake has been definitively shown to decrease the incidence of major cardiovascular events, lower circulating triglycerides, and improve overall vascular endothelial function [15, 22, 23]. Beyond their cardioprotective roles, these compounds are critical for neurological integrity. DHA is a major structural lipid in the human brain and retina for the prevention of cognitive decline in aging populations [11, 18, 24, 25]. Emerging clinical evidence also demonstrates that modulating the

pineal gland's cellular membrane structure with EPA and DHA can enhance melatonin production, thereby regulate human sleep patterns, while concurrently provide measurable relief from anxiety and clinical depression [26]. Additionally, their consumption is linked to a lowered risk of specific cancers, alongside measurable improvements in bone mineralization and muscle preservation [9, 20, 27].

The rising demand for these beneficial compounds, coupled with the limitations of traditional sources, has highlighted the urgent need for alternative and sustainable production methods, with microorganisms emerging as a promising solution [8, 22, 45]. Historically, providing a sufficient supply of these specialized molecules relied almost entirely on marine fish harvesting. However, marine sources face severe existential threats due to global overfishing, environmental accumulation of ocean contaminants, like heavy metals, and climate change-induced temperature elevations that progressively diminish the natural synthesis of oceanic EPA and DHA [28–42, 46–48]. To circumvent these ecological and supply-chain barriers, advanced biotechnological platforms utilizing microbial cell factories have rapidly developed [43, 44, 49–146]. Diverse, sustainable systems employing marine bacteria [2, 142, 143], diatoms [16, 86, 88, 97, 104], algae/microalgae [29, 30, 59, 112, 144], thraustochytrids [4, 59, 81, 111, 136], and metabolically engineered yeasts, such as *Yarrowia lipolytica*/*Kluyveromyces* / [22, 23, 130, 131, 141], fungi are now highly optimized via large-scale heterotrophic fermentation [131]. Not only do these microbial factories provide a more consistent, contamination-free, and vegan-friendly source of essential lipids, but they also offer a highly scalable pathway to sustainably meet the surging global nutritional and therapeutic demands [134].

METHODOLOGY

The present review work has been carried out by citing the recent scientific literature and data. The literature was retrieved from PubMed, Google Scholar, Academia Edu, Live-DNA, Wiley-Online, Cochrane database, and manual search from Elsevier, Springer, and Taylor & Francis databases. A total of 370 research articles were pooled, and 146 were selected for the present study using PRISMA guidelines

Biological and Therapeutic Importance of Polyunsaturated Fatty Acids (PUFAs) – Omega-3 Fatty Acids

Omega-3 PUFAs play a pivotal role in maintaining overall human health and development, including functions in the brain, eye, and cardiovascular system.

Health Benefits

- *Nervous System and Brain Health:* DHA is essential for proper neurological and visual development in infants and children. Both EPA and DHA are vital for brain function, memory, and can help prevent neurodegenerative diseases, psychiatric disorders, and improve conditions [57, 58, 65, 75]. They influence neuronal gene expression and maintain cell membrane fluidity and integrity [56].
- *Cardiovascular Health:* Omega-3 FAs are cardioprotective, reducing the risk of cardiovascular diseases (CVDs) by lowering serum triglyceride concentrations, protecting against atherosclerosis, and exhibiting anti-arrhythmic, anti-thrombotic, and anti-atherosclerotic properties [1]. They can also help reduce inflammation and improve blood lipid profiles.
- *Anti-inflammatory and Antioxidant Properties:* EPA and DHA reduce the synthesis of inflammatory eicosanoids and reactive oxygen species, giving rise to anti-inflammatory mediators like resolvins [52, 53, 145]. The anti-inflammatory mechanism involves G protein-coupled receptor 120 (GPR120) as an omega-3 PUFA receptor/sensor. Omega-3 PUFAs also act as antioxidants, protecting cells from oxidative damage [9, 55].
- *Cancer Prevention:* EPA and GLA have shown anti-cancer properties, particularly against certain types of cancer cells [98].
- *Infectious Diseases:* EPA and DHA have demonstrated therapeutic significance against several microbial pathogens, including bacteria, fungi, and viruses [41, 44, 50, 53]. They inhibit bacterial

growth, induce cell death in *Plasmodium* species, and exert anti-hepatitis C virus activity. Their antimicrobial mechanisms include altering cell membrane properties (hydrophobicity, surface charge, integrity), inhibiting virulence factor gene expression, disrupting cell-to-cell communication, and blocking fatty acid synthesis enzymes like FabI [92, 96, 138]. These bioactives obtained from *Chlamydomonas reinhardtii* have been found to inhibit tuberculosis-causing *Mycobacterium tuberculosis* *in vivo* [66, 68].

Physiological Role in Microorganisms

PUFAs, particularly EPA, are vital for microorganisms to adapt and survive in extreme environments such as deep seas and polar regions. A high PUFA content in bacterial cell membranes helps maintain membrane fluidity, which is crucial for coping with low temperatures and high hydrostatic pressure. EPA also contributes to cell division, membrane organization, and acts as an antioxidant, scavenging free radicals and protecting against oxidative damage [6, 146]. The presence of EPA in fungal membranes can also enhance resistance against water-soluble antibiotics by improving the biosynthesis of membrane proteins like porins [122].

MICROBIAL PRODUCTION OF OMEGA-3 FATTY ACIDS

Why Microbial PUFAs?

Despite the significant health benefits of omega-3 PUFAs, their traditional sources, primarily fish and certain plants, present several limitations. Plant sources predominantly contain short-chain ALA, with limited EPA and DHA content [54, 99, 107, 108]. Fish oil, while rich in EPA and DHA, is associated with issues, such as undesirable odor and flavor, potential heavy metal and contaminant (mercury, dioxins) contamination, and concerns about the sustainability of fish populations due to overfishing. The global demand for DHA is projected to exceed supply significantly [105].

Microorganisms offer a highly promising and sustainable alternative source for PUFA production [96, 133] due to several advantages, because these can be cultured in controlled bioreactor environments regardless of climate, season, or geographical location, offering a consistent supply [102, 103]. They can utilize a wide variety of low-cost substrates, including agro-industrial wastes [8, 25, 27–29, 40, 45–47, 62, 140], which reduces production costs and offers an environmentally beneficial waste disposal method [65, 69, 118, 119]. Microorganisms can produce specific types of PUFAs, often as a single product rather than a mixture, which simplifies purification and lowers overall production costs and is non-toxic [73, 76, 109]. Microbes have fast growth rates and simpler genetic structures compared to plants and animals, making them ideal models for researching PUFA metabolic pathways and for genetic manipulation to maximize productivity and tailor fatty acid profiles even on waste materials [106, 120], unsterilized substrates, and production conditions [124, 128]. Microbial oils, often referred to as single-cell oils (SCOs), can be produced under sterile and controlled conditions, minimizing contamination risks (Figure 2). They also often contain natural antioxidants, like carotenoids, which protect PUFAs from auto-oxidation and offer a longer shelf-life, and are generally recognized as safe (GRAS) for human consumption.

Types of PUFA-Producing Microorganisms

Oleaginous microorganisms are defined as species that can accumulate lipids exceeding 20% of their total dry biomass weight. This includes bacteria, fungi, and microalgae (Table 1).

Biosynthesis Pathways

Microbes synthesize PUFAs through two primary metabolic mechanisms, the Desaturase/Elongase (Aerobic) Pathway [15, 79], common in eukaryotes and some prokaryotes, which involves a series of desaturase [31] and elongase enzymes [39]. In eukaryotes, these enzymes are typically associated with the endoplasmic reticulum membrane (Figure 2). Second, Polyketide Synthase s(PKS) (Anaerobic) Pathway [42], where some prokaryotes and eukaryotes (e.g., *Shewanella* sp.) and thraustochytrids, utilize a PKS-like multi-functional enzyme complex to synthesize DHA or EPA (26, 32,64). This pathway can produce PUFAs without the direct involvement of fatty acid synthase (FAS, 71-73) or aerobic desaturase/elongase enzymes (Figure 2a). The PKS genes are often clustered, and their presence in diverse species suggests lateral gene transfer.




Figure 2. Microbial production of EPA, DHA.

Table 1. Important PUFAs and their microbial sources.

PUFA	Microbial sources
ARA	Fungi (<i>Mortierella alpina</i> , <i>Entomophthora exitalis</i> , <i>Blastocladiella emersonii</i> , <i>Conidiobolus nanodes</i>); Algae (<i>Euglena gracilis</i> , <i>Sargassum salicifolium</i> , <i>Porphyridium cruentum</i> , <i>Heterocapsa tricus</i> , <i>Amphidinium sp.</i> , <i>Prorocentrum minimum</i> , <i>Prorocentrum triestinum</i> , <i>Tetraselmis chui</i>); Bacteria (<i>Phaeocystis flava</i>).
DGLA	Fungi (<i>Conidiobolus nanodes</i> , <i>Mortierella alpina</i> , <i>Saprolegnia ferax</i>)
DHA	Fungi (<i>Thraustochytrium roseum</i> , <i>Thraustochytrium aureum</i> , <i>Schizochytrium aggregatum</i> , <i>Schizochytrium SR21</i>); Algae (<i>Cryptocodinium cohnii</i> , <i>microalgae MK8805</i> , <i>Gyrodinium nelsoni</i> , <i>Gonyaulax polyedra</i> , <i>Amphidinium carteri</i> , <i>Amphidinium sp.</i> , <i>Alexandrium sanguinea</i> , <i>Heterocapsa triquetra</i> , <i>Isochrysis galbana</i> , <i>Pavlova gyraus</i> , <i>Prorocentrum micans</i> , <i>Prorocentrum minimum</i> , <i>Scripsiella trochoidea</i>); Bacteria (<i>Rhodospseudomonas spp.</i> , <i>Vibrio spp.</i> , <i>Colwellia psychrerythraea</i>).
DPA	Fungi (<i>Schizochytrium sp.</i>).
EPA	Fungi (<i>Mortierella alpina</i> , <i>M. elongata</i> , <i>Pythium ultimum</i> , <i>P. irregulare</i>); Algae (<i>Chlorella minutissima</i> , <i>Amphidinium sp.</i> , <i>Alexandrium sanguinea</i> , <i>Asterionella sp.</i> , <i>Chlamydomonas sp.</i> , <i>Chlorella ellipsoidea</i> , <i>Heterosigma akashiwo</i> , <i>Nannochloropsis sp.</i> , <i>Nitschia ovalis</i> , <i>Pavlova gyraus</i> , <i>Phaeodactylum tricornutum</i> , <i>Tribonema sp.</i>); Bacteria (<i>Shewanella putrefaciens</i> , <i>Shewanella electrodiffila</i>).
ETA	Fungi (<i>Mortierella alpina</i>).
GLA	Fungi (<i>Mucor circinelloides</i> , <i>Mortierella isabellina</i> , <i>M. mucedo</i> , <i>M. ramanniana</i> , <i>Cunninghamella elegans</i> , <i>C. echinulata</i> , <i>C. japonica</i> , <i>Thamnidium elegans</i> , <i>Rhizopus arrhizus</i> , <i>Gilbertella persicaria</i>); Algae (<i>Chlorella vulgaris</i> , <i>Spirulina platensis</i> , <i>Amphidinium sp.</i> , <i>Dunaliella salina</i> , <i>Isochrysis galbana</i> , <i>Tetraselmis chui</i> , <i>Tetraselmis suecica</i> , <i>P. parvum</i>).
MA	Fungi (<i>Mortierella alpina</i>).
SDA	Fungi (<i>Mortierella alpina</i>).




Figure 2(a). Microbial metabolic pathways to produce PUFA.

Table 2. Summary of genetic engineering strategies in microbes for PUFA production.

Genes targeted	Host organism	Resulting PUFAs/effect
DHA synthesis gene cluster (from <i>M. marina</i> MP-1); <i>pfa</i> gene cluster (Source: <i>A. fasciculatus</i>)	<i>E. coli</i> DH5a, <i>P. putida</i>	Increased DHA production.
EPA synthesis gene cluster (Source: <i>Shewanella</i> sp.)	<i>E. coli</i> JM109, <i>S. baltica</i> MAC1, <i>C. synechococcus</i>	Increased EPA production.
EPA/DHA synthesis gene cluster (Source: <i>Shewanella</i> sp.)	<i>L. lactis</i> subsp. <i>cremoris</i>	EPA/DHA production.
Overexpression of desaturase/ elongase genes (e.g., D6-Des, D9-Des, x3-Des, D6-Elo, D5-Des)	<i>S. cerevisiae</i> , <i>Y. lipolytica</i>	Production of EPA, DPA, DHA, GLA, ALA; 56.6% EPA and 18.3% DPA/5.6% DHA in <i>Y. lipolytica</i> ; Increased GLA in <i>Y. lipolytica</i> (20.2% of TFAs).
Overexpression of malic enzyme (<i>malce1</i>), glucose-6-phosphate dehydrogenase (<i>g6pd</i>), <i>leuB</i>	<i>M. circinelloides</i>	Increased GLA production (2.5-fold increase in lipid accumulation).
Overexpression of GLA elongase (<i>GLELO</i>), delta-15 desaturase	<i>M. circinelloides</i>	Production of DGLA, SDA.
Overexpression of <i>malce1</i> , <i>glelo</i> , D17-desaturase	<i>M. alpina</i>	Increased ARA production; conversion of ARA to EPA (boosted EPA to 31.5% of TFAs).
Overexpression of malonyl CoA-acyl carrier protein transacylase (MCAT), glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidate acyltransferase (LPAAT/AGPAT), diacylglycerol acyltransferases (DGATs)	<i>P. tricornutum</i> , <i>N. oceanica</i>	Increased total lipid content (31% in <i>N. oceanica</i>), increased EPA (8% in <i>N. oceanica</i> , 40% in <i>P. tricornutum</i>), increased DHA and EPA (1.5-fold in <i>P. tricornutum</i>); Increased TAG-associated PUFAs (184%).
Overexpression of fatty acid desaturases (FADs) and elongases (ELOs)	<i>N. oceanica</i> , <i>T. pseudonana</i> , <i>P. tricornutum</i>	Increased EPA (25%), increased EPA and DHA (12% and 150%, respectively), accumulation of DHA, EPA, ARA.
RNA interference (RNAi) knockdown of UGPase, chrysolaminarin synthase, TAG lipase, phosphoenolpyruvate carboxykinase (PEPCK)	<i>P. tricornutum</i> , <i>T. pseudonana</i>	Increased lipid content (24% in <i>P. tricornutum</i> , 2.4-fold in <i>T. pseudonana</i>); increased EPA in TAGs (70%); boosted lipid accumulation (40%).
Overexpression of G6PDH, malic enzyme (ME)	<i>Aurantiochytrium</i> sp. SD116, <i>P. tricornutum</i>	Enhanced LC-PUFAs (DPA and DHA by 25% and 12.5%, respectively); increased DHA production (up to twofold).

METABOLIC ENGINEERING FOR ENHANCED PUFA PRODUCTION

Metabolic engineering is a powerful approach to modify the lipid composition [67] and enhance PUFA production in oleaginous microbes (Table 2). Strategies include overexpression [84, 85] or blocking/knockout of genes, and knockdown or activation of regulatory elements involved in PUFA synthesis and storage (Table 3).

BIOCONVERSION OF AGRO-INDUSTRIAL WASTES FOR SCO PRODUCTION

A significant advancement in sustainable PUFA production is the bioconversion of low-cost agro-industrial wastes into high-value single-cell oils (SCOs) by oleaginous microorganisms (Table 3). These wastes are rich in minerals, nitrogen, and carbon sources, making them suitable growth substrates.

Oleaginous microbes can utilize both hydrophilic and hydrophobic substrates. “*De novo*” lipid fermentation typically produces large amounts of lipids from simple carbon sources, like sugars, while “*Ex novo*” lipid fermentation transforms existing extracellular or intracellular lipids from complex hydrophobic materials, like waste cooking oils or dairy effluents, into desired fatty acid profiles. Genetic manipulation of microbes to directly convert lignocellulosic biomass or to produce lipases that facilitate hydrophobic substrate utilization further enhances the efficiency of this bioconversion.

Table 3. Bioconversion of agro-industrial wastes into high-value SCO by oleaginous microbes.

Microorganisms	Substrate	PUFAs produced
<i>M. isabelline</i>	Corn stover, douglas fir forest waste, sweet sorghum, rice hull hydrolysates.	GLA.
<i>C. echinulate</i>	Waste from edible oil plants, potato industry starch waste, tomato hydrolysate enriched with glucose, corn steep liquor, soybean oil waste.	GLA.
<i>M. recurves</i>	Hydrolyzed molasses.	GLA.
<i>Mucor circinelloides</i> , <i>M. isabellina</i> , <i>Rhizopus</i> sp.	Liquid waste from cheese-making process, cooking oil (soybean, sesame, canola, palm).	GLA.
<i>T. elegans</i> , <i>C. echinulata</i>	Sugar-based and corn steep lignocellulosic wastes.	GLA.
<i>Schizochytrium</i> sp. DT3, <i>S. Mangrovei</i>	Cannabis sativa (hemp) biomass, coconut water.	DHA.
<i>P. tricornutum</i>	Birch and spruce biomass.	EPA, DHA.
<i>Trichosporon oleaginosus</i>	Xylose-containing substrates.	ETA, EDA.
<i>Aurantiochytrium</i> sp., <i>Schizochytrium</i> sp.	Sugarcane bagasse hydrolysate, orange peel extracts, by-product of palm oil industry.	DHA.
<i>T. kinney</i> , <i>S. limacinum</i> , <i>T. elegans</i> , <i>U. isabellina</i> , <i>C. echinulata</i> , <i>Z. moelleri</i> , <i>Mucor.</i> , <i>Mortierella</i> sp.	Crude glycerol.	DHA, GLA, ARA, DGLA.
<i>Navicula</i> sp., <i>Chlorella</i> sp., <i>Nannochloropsis</i> sp.,	Phosphate-limited wastewaters from aquaculture stations, shrimp farm wastewaters.	EPA.
<i>Euglena gracilis</i> , <i>Selenastrum</i> sp.	Fish farm wastewater.	ALA, ARA, EPA, DHA.
<i>Mortierella</i> sp.	Shrimp shell wastes.	ARA, DGLA.
<i>Mortierella alpina</i> CFR-GV15	Linseed oil and garden cress oil.	ALA, EPA, DHA.

NOVEL SOURCES AND SCREENING APPROACHES FOR MICROBIAL PUFAS

Given that only a small fraction of microbial diversity has been studied, researchers are actively exploring new avenues to discover and develop novel PUFA-producing strains. Underexplored ecosystems, such as hyperarid deserts, high-saline environments, and especially the deep-sea and polar regions, are rich reservoirs of novel microorganisms with unique adaptations and PUFA-producing capabilities. Deep-sea bacteria, like *Shewanella* species, are known for producing significant amounts of EPA and DHA to thrive in psychrophilic (cold-loving) and piezophilic (pressure-loving) conditions. Many microorganisms are difficult to cultivate in laboratories due to specialized growth requirements. Developing tailored media and utilizing signaling molecules can help isolate and grow these rare microbes, potentially uncovering new PUFA sources. HTS approaches, incorporating automated screening and advanced analytical techniques (e.g., GC, LC, MS, NMR, MALDI, FTIR, etc.), enable rapid identification, profiling, and characterization of lipid composition in large numbers of microbial strains [116].

Cultivating two or more microorganisms together (co-culturing) or exposing cells to specific signals (“elicitors”) can activate silent gene clusters [129] and induce the production of novel or enhanced metabolites, including PUFAs [75]. Advances in sequencing technology allow for comprehensive genomic analysis, revealing the full metabolic potential of microorganisms, including hidden PUFA biosynthetic gene clusters [95, 114]. Comparative genomics helps identify key genes and pathways associated with high lipid accumulation [126].

Genetic Engineering Method Development in Thraustochytrids

Thraustochytrids, unicellular heterotrophic marine eukaryotes, are highly regarded for their ability to store large amounts of DHA and other ω 3-PUFAs [80]. Developing genetic engineering tools for these non-model organisms is crucial but challenging due to strain-specific variations in transformation protocols.

DNA Transformation Methods

The most common methods for delivering DNA into thraustochytrid cells are electroporation, biolistic transformation, and *Agrobacterium*-mediated transformation (AMT).

- *Electroporation*: This is the most frequently used method, involving electric pulses to create temporary pores in cell membranes for DNA uptake. Parameters, such as pulse type (exponential decay, square wave), number of pulses, electric field strength (1.8 to 10 kV/cm), and pulse length (0.65 to 25 ms), are critical and vary by strain. Pre-treatment of cells, especially cell wall disruption (e.g., with dithiothreitol (DTT) or enzymatic treatments), and the use of non-ionic osmotic stabilizers – like sorbitol or sucrose in electroporation solutions – can significantly improve efficiency [129].
- *Biolistic Transformation (Particle Bombardment)*: This method uses high-pressure helium to inject DNA-coated metal particles into cells. While less common currently, it has been successful where electroporation failed in some strains.
- *Agrobacterium-Mediated Transformation (AMT)*: This cost-effective method utilizes *Agrobacterium tumefaciens* to integrate large DNA fragments (up to 150 kb) into the host genome, typically as a single copy [32]. It has been successfully applied to engineer *Schizochytrium* species [33].

Other Strategies for DNA Transfer

Novel and emerging methods for DNA transfer are also being explored:

- *Conjugation*: This bacterial-based method transfers plasmids between donor *E. coli* and recipient cells via conjugative bridges, eliminating the need for expensive equipment and offering high transformation efficiency [104].
- *Digital Microfluidics Electroporation*: This approach uses tiny oily droplets to encapsulate cells and DNA, significantly reducing required voltages and increasing transformation efficiency by minimizing water electrolysis and improving heat dissipation.
- *Cell-Penetrating Peptides (CPPs)*: Small peptides (e.g., TAT peptide, pVEC) can facilitate intracellular transport of biological materials, like DNA or Cas9-gRNA ribonucleoprotein (RNP) complexes across cell membranes, offering a simpler transformation procedure [103].

DNA Properties and Genome Integration

The properties and design of the transforming DNA significantly influence the outcome:

- *Genome Integration Mechanisms*: DNA can be integrated into the host genome either by homologous recombination (HR), utilizing sequence homology, or by non-homologous end joining (NHEJ), which integrates DNA at random double-strand breaks [10]. In most microalgae, random integration is more efficient, but HR allows for targeted gene editing.
- *Homology Arms*: HR efficiency can be enhanced by increasing the length of homology arms flanking the desired gene cassette [13].
- *DNA Structure and Quantity*: Both linear and circular DNA have been used. Linear DNA may be more advantageous for HR. Using higher amounts of DNA (e.g., 1 to 20 µg per electroporation) can increase the number of transformants.

Facilitating HR:

- *CRISPR-Cas System*: This genome-editing technique uses sequence-specific nucleases (e.g., Cas9) and guide RNA to induce DSBs at precise genomic locations, greatly increasing HR efficiency for targeted deletions, insertions, or nucleotide changes [87]. It has been successfully applied in *Aurantiochytrium* species [102].
- *Interfering with NHEJ*: Downregulating NHEJ-specific enzymes, like DNA ligase type IV, can increase the rate of homologous recombination by reducing the competition from random integration.
- *Extrachromosomal DNAs*: The use of autonomously replicating episomes and plasmids can reduce the potential side effects of random genomic integration and allow for easy removal of the DNA from cells by removing selection pressure.

Gene Expression in Thraustochytrids

Controlling gene expression is crucial for successful genetic engineering:

- **Promoters and Terminators:** The choice of promoter (regulating transcription initiation) and terminator (regulating transcription termination) significantly affects gene expression levels [14].
 - **Constitutive Promoters:** Commonly used promoters include the elongation factor 1- α (EF1 α) promoter (endogenous and from *Saccharomyces cerevisiae* TEF1) and the glucose-repressible gene (ccg1) promoter of *Neurospora*.
 - **Inducible Promoters:** These allow controlled expression of genes, particularly toxic ones. Examples include the galactose-inducible *GAL1* promoter (*S. cerevisiae*), ethanol-inducible alcohol dehydrogenase I (*AlcA*) promoter (*Aspergillus nidulans*), and methanol-inducible alcohol oxidase I (*AOX1*) promoter (*Pichia pastoris*).
- **Antibiotic Resistance Genes:** Antibiotics are widely used for selecting transformants expressing the resistance gene. Commonly used antibiotics in thraustochytrids include G418, zeocin, and hygromycin (Table 4). The optimal concentrations vary significantly between strains and even within the same strain across different protocols.

Table 4. Antibiotics used for selecting thraustochytrid transformants (in $\mu\text{g/mL}$).

Strain	Zeocin ($\mu\text{g/mL}$)	Hygromycin ($\mu\text{g/mL}$)	G418 ($\mu\text{g/mL}$)	Blasticidin ($\mu\text{g/mL}$)	Other ($\mu\text{g/mL}$)
<i>A. limacinum</i>	2000	500	–	–	–
<i>A. limacinum mh0186</i>	500, 2000	500	1200	–	500 (neomycin)
<i>A. limacinum OUC168</i>	5	–	–	–	100 (chloramphenicol)
<i>A. limacinum SR21</i>	30, 50, 100	200	500	–	–
<i>Aurantiochytrium sp. KRS101</i>	–	–	–	–	30 (cycloheximide)
<i>Aurantiochytrium sp. MP4</i>	50	–	–	–	–
<i>Aurantiochytrium sp. PKU#SW7</i>	500	500	–	–	–
<i>Aurantiochytrium sp. RH-7A</i>	100	–	–	–	–
<i>Aurantiochytrium sp. SD116</i>	30, 50, 100	500	50	–	100 (Tetracycline)
<i>Parietichytrium sp. TA04Bb</i>	2000	500	800	–	–
<i>Schizochytrium sp. S31</i>	40, 50	100	–	–	50 (bleomycin), 250 (cefotaxime), 50 (paromomycin)
<i>Schizochytrium sp. HX-308</i>	1.5, 20	–	–	–	–
<i>Schizochytrium sp. PKU#Mn4</i>	800	–	–	–	–
<i>Schizochytrium sp. TIO01</i>	–	–	100	–	–
<i>Schizochytrium sp. TIO1101</i>	300	–	–	–	–
<i>Schizochytrium sp. SEK 579</i>	2000	500	–	–	–
<i>Schizochytrium sp. CB15-5</i>	20	–	–	–	–
<i>Thraustochytrid strain 12B</i>	500	–	–	–	–
<i>T. aureum ATCC 34304</i>	2000	1000, 2000	200–400	–	–
<i>Thraustochytrium sp. ONC-T18</i>	250	400	–	–	–

- *Expression of Multiple Genes:* To reduce cassette size and enhance DNA delivery, multiple genes can be linked using *2A linker sequences* (viral-origin peptides that induce polypeptide cleavage during translation), allowing them to be expressed as a single multicistronic transcription unit [4]. Alternatively, genes of interest and antibiotic resistance genes can be on separate DNA molecules and co-transformed.

SAFETY, TOXICITY, AND COST OF MICROBIAL PUFAS

Microbial oils are generally composed of triacyl glycerides and sterols like plant and animal oils. Rigorous safety assessments are required for their use in food [37]. Studies have shown that DHA-rich and EPA-rich algal oils are safe for human consumption, with no observed toxic effects or mutagenicity at high concentrations [1]. Concerns about contaminants found in fish oil are largely absent in microbial oils due to controlled production environments [76]. The cost of microbial oil production is a significant factor, with substrate costs accounting for 60% to 75% of the total price (Table 5), compared with plant oils.

Table 5. Lipid productivity comparison of selected oleaginous microbes and plants.

Source (microbe and plant)	Oil yield (kg/m ³ /year)	Oil yield (kg/ha/year)
<i>R. toruloides</i>	2120	–
<i>C. curvatus</i>	1154	–
<i>M. isabelline</i>	679	–
<i>C. echinulate</i>	134	–
<i>C. gracilis</i>	525	–
<i>S. limacinum</i>	404	–
Sunflower	–	500–700
Soybean	–	450–500
Palm	–	3000–5000

FUTURE PERSPECTIVES AND CONCLUDING REMARKS

The increasing global demand for essential omega-3 PUFAs, coupled with the limitations of conventional sources, underscores the critical need for sustainable and efficient production methods. Microbial production of PUFAs offers a promising solution, with significant advantages in terms of sustainability, safety, and versatility.

Future research should focus on continuing to explore underexplored microbial habitats and applying advanced HTS and genome-mining techniques to uncover new, high-yielding PUFA producers. Further refining metabolic engineering strategies to maximize PUFA yield and tailor fatty acid profiles in existing and novel oleaginous microbes. This includes a deeper understanding of lipid metabolism, precursor molecule generation, and cofactor production (e.g., NADPH). Developing more robust and universally applicable genetic manipulation protocols for non-model organisms like thraustochytrids, potentially leveraging emerging technologies such as CRISPR-Cas, conjugation, microfluidics, and cell-penetrating peptides. Prioritizing the utilization of diverse low-cost agro-industrial wastes and exploring efficient biomass recovery and lipid extraction procedures to improve the economic viability of microbial PUFAs. Implementing biorefinery concepts for the total exploitation of microbial oils can further address cost challenges.

A multidisciplinary approach involving nutritionists, microbiologists, molecular biologists, and natural product chemists is essential to accelerate the development and industrial scaling of PUFA production from microorganisms. This shift towards microbial sources represents a significant step towards meeting global nutritional needs and promoting environmental sustainability.

REFERENCES

1. Abe E, Ikeda K, Nutahara E, Hayashi M, Yamashita A, Taguchi R, et al. Correction: Novel lysophospholipid acyltransferase PLAT1 of *Aurantiochytrium limacinum* F26-b responsible for

- generation of palmitate-docosahexaenoate-phosphatidylcholine and phosphatidylethanolamine. *PLoS One*. 2018;13(8):e0203016. doi: 10.1371/journal.pone.0203016.
2. Abdelmohsen UR, Grkovic T, Balasubramanian S, Kamel MS, Quinn RJ, Hentschel U. Elicitation of secondary metabolism in actinomycetes. *Biotechnol Adv*. 2015;33(6):798–811. Doi: 10.1016/j.biotechadv.2015.06.003.
 3. Abeln F, Chuck CJ. The history, state of the art and future prospects for oleaginous yeast research. *Microb Cell Fact*. 2021;20(1):1–31. doi: 10.1186/s12934-021-01712-1.
 4. Adachi T, Sahara T, Okuyama H, Morita N. Glass bead-based genetic transformation: An efficient method for transformation of thraustochytrid microorganisms. *J Oleo Sci*. 2017;66(7):791–795. doi: 10.5650/jos.ess17084.
 5. Alakhras R, Bellou S, Fotaki G, Stephanou G, Demopoulos NA, Papanikolaou S, et al. Fatty acid lithium salts from *Cunninghamella echinulata* have cytotoxic and genotoxic effects on HL-60 human leukemia cells. *Eng Life Sci*. 2015;15(2):243–253. doi: 10.1002/elsc.201400208.
 6. Albataineh H, Stevens DC. Marine myxobacteria: A few good halophiles. *Mar Drugs*. 2018;16(6):209. doi: 10.3390/md16060209.
 7. Bianchi AC, Olazábal L, Torre A, Loperena L. Antarctic microorganisms as source of the omega-3 polyunsaturated fatty acids. *World J Microbiol Biotechnol*. 2014;30(6):1869–1878. doi: 10.1007/s11274-014-1607-2.
 8. Chander M, Kaur J. Aquatic ecosystems: A review on prospecting of anticancer molecules from fungi & other microbes. *Int J Fungi*. 2024;1(2).
 9. Albonetti S, Minardi P, Trombetti F, Savigni F, Mordenti AL, Baranzoni GM, et al. In vivo and in vitro effects of selected antioxidants on rabbit meat microbiota. *Meat Sci*. 2017;123:88–96. doi: 10.1016/j.meatsci.2016.09.004.
 10. Amiri Moghaddam J, Poehlein A, Fisch K, Alanjary M, Daniel R, König GM, et al. Draft genome sequences of the obligatory marine myxobacterial strains *Enhygromyxa salina* SWB005 and SWB007. *Genome Announc*. 2018;6(17):e00324–18. doi: 10.1128/genomeA.00324-18.
 11. Amiri-Jami M, Lapointe G, Griffiths MW. Engineering of EPA/DHA omega-3 fatty acid production by *Lactococcus lactis* subsp. *cremoris* MG1363. *Appl Microbiol Biotechnol*. 2014;98(7):3071–3080. doi: 10.1007/s00253-013-5381-0.
 12. Ami D, Posterl R, Mereghetti P, Porro D, Doglia SM, Branduardi P. Fourier transform infrared spectroscopy as a method to study lipid accumulation in oleaginous yeasts. *Biotechnol Biofuels*. 2014;7(1):12. doi: 10.1186/1754-6834-7-12.
 13. Angstenberger M, Krischer J, Aktaş O, Büchel C. Knock-down of a ligIV homologue enables DNA integration via homologous recombination in the marine diatom *Phaeodactylum tricornutum*. *ACS Synth Biol*. 2019;8(1):57–69. doi: 10.1021/acssynbio.8b00234.
 14. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. *Nat Biotechnol*. 2020;38(7):824–844. doi: 10.1038/s41587-020-0561-9.
 15. Bañuelos-Hernández B, Monreal-Escalante E, González-Ortega O, Angulo C, Rosales-Mendoza S. Algevir: An expression system for microalgae based on viral vectors. *Front Microbiol*. 2017;8:1100. doi: 10.3389/fmicb.2017.01100.
 16. Barka F, Angstenberger M, Ahrendt T, Lorenzen W, Bode HB, Büchel C. Identification of a triacylglycerol lipase in the diatom *Phaeodactylum tricornutum*. *Biochim Biophys Acta*. 2016;1861(3):239–248. doi: 10.1016/j.bbailip.2015.12.023.
 17. Bayne AC, Boltz D, Owen C, Betz Y, Maia G, Azadi P, et al. Vaccination against influenza with recombinant hemagglutinin expressed by *Schizochytrium* sp. confers protective immunity. *PLoS One*. 2013;8(4):e61790. doi: 10.1371/journal.pone.0061790.
 18. Bellou S, Moustogianni A, Makri A, Aggelis G. Lipids containing polyunsaturated fatty acids synthesized by zygomycetes grown on glycerol. *Appl Biochem Biotechnol*. 2012;166(1):146–158. doi: 10.1007/s12010-011-9411-z.
 19. Bentsen H. Dietary polyunsaturated fatty acids, brain function and mental health. *Microb Ecol Health Dis*. 2017;28(Suppl 1):1281916. doi: 10.1080/16512235.2017.1281916.

20. Bharathiraja B, Sridharan S, Sowmya V, Yuvaraj D, Praveenkumar R. Microbial oil - A plausible alternate resource for food and fuel application. *Bioresour Technol.* 2017;233:423–432. doi: 10.1016/j.biortech.2017.03.006.
21. Calo JR, Crandall PG, O'Bryan CA, Ricke SC. Essential oils as antimicrobials in food systems- A review. *Food Control.* 2015;54:111–119. doi: 10.1016/j.foodcont.2014.12.040.
22. Cao M, Gao M, Lopez-Garcia CL, Wu Y, Seetharam AS, Severin AJ, et al. Centromeric DNA facilitates nonconventional yeast genetic engineering. *ACS Synth Biol.* 2017;6(8):1545–1553. doi: 10.1021/acssynbio.7b00046.
23. Carsanba E, Papanikolaou S, Erten H. Production of oils and fats by oleaginous microorganisms with an emphasis given to the potential of the nonconventional yeast *Yarrowia lipolytica*. *Crit Rev Biotechnol.* 2018;38(8):1230–1243. doi: 10.1080/07388551.2018.1472065.
24. Cerone M, Smith TK. A brief journey into the history of and future sources and uses of fatty acids. *Front Nutr.* 2021;8:570401. doi: 10.3389/fnut.2021.570401.
25. Chalimaa A, Hatzidakia A, Karnaouri A, Topakas E. Integration of a dark fermentation effluent in a microalgal-based biorefinery for the production of high-added value omega-3 fatty acids. *Appl Energy.* 2019;152:102–109.
26. Chan LG, Cohen JL, Ozturk G, Hennebelle M, Taha AY, L N de Moura Bell JM. Bioconversion of cheese whey permeate into fungal oil by *Mucor circinelloides*. *J Biol Eng.* 2018;12:25. doi: 10.1186/s13036-018-0116-5.
27. Chander M. Nutraceuticals: Microbiology & Biotechnology. National Conference on Latest Developments in Science, Engineering & Management. 2014:443–449. doi: 10.13140/2.1.2177.3124.
28. Chander M. Marine Microbial Ecology: A Comprehensive Review of Interactions, Symbiosis, and Bioprospecting. *Int J Mar Life.* 2026;3(1):30–37. doi: 10.37591/IJML.v03i01.239774.
29. Chen CY, Lee MH, Dong CD, Leong YK, Chang JS. Enhanced production of microalgal lipids using a heterotrophic marine microalga *Thraustochytrium* sp. BM2. *Biochem Eng J.* 2020;154:107429. doi: 10.1016/j.bej.2019.107429.
30. Chen CY, Nagarajan D, Cheah WY. Eicosapentaenoic acid production from *Nannochloropsis oceanica* CY2 using deep sea water in outdoor plastic-bag type photobioreactors. *Bioresour Technol.* 2018;253:1–7. doi: 10.1016/j.biortech.2017.12.102.
31. Chen JW, Liu WJ, Hu DX, Wang X, Balamurugan S, Alimujiang A, et al. Identification of a malonyl CoA-acyl carrier protein transacylase and its regulatory role in fatty acid biosynthesis in oleaginous microalga *Nannochloropsis oceanica*. *Biotechnol Appl Biochem.* 2017;64(5):620–626. doi: 10.1002/bab.1531.
32. Cheng CL, Huang SJ, Wu CL, Gong HY, Ken CF, Hu SY, et al. Transgenic expression of omega-3 PUFA synthesis genes improves zebrafish survival during *Vibrio vulnificus* infection. *J Biomed Sci.* 2015;22:103. doi: 10.1186/s12929-015-0208-1.
33. Cheng R, Ma R, Li K, Rong H, Lin X, Wang Z, et al. *Agrobacterium tumefaciens* mediated transformation of marine microalgae *Schizochytrium*. *Microbiol Res.* 2012;167(3):179–186. doi: 10.1016/j.micres.2011.05.003.
34. Cheirsilp B, Suwannarat W, Niyomdecha R. Mixed culture of oleaginous yeast *Rhodotorula glutinis* and microalga *Chlorella vulgaris* for lipid production from industrial wastes and its use as biodiesel feedstock. *N Biotechnol.* 2011;28(4):362–368. doi: 10.1016/j.nbt.2011.01.004.
35. Cheirsilp B, Kitcha S, Torpee SJ. Co-culture of an oleaginous yeast *Rhodotorula glutinis* and a microalga *Chlorella vulgaris* for biomass and lipid production using pure and crude glycerol as a sole carbon source. *Ann Microbiol.* 2012;62(3):987–993.
36. Cholewski M, Tomczykowa M, Tomczyk M. A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids. *Nutrients.* 2018;10(11):1662. doi: 10.3390/nu10111662.
37. Collins ML, Lynch B, Barfield W, Bull A, Ryan AS, Astwood JD. Genetic and acute toxicological evaluation of an algal oil containing eicosapentaenoic acid (EPA) and palmitoleic acid. *Food Chem Toxicol.* 2014;72:162–168. doi: 10.1016/j.fct.2014.07.021.

38. Colombo SM, Rodgers TFM, Diamond ML, Bazinet RP, Arts MT. Projected declines in global DHA availability for human consumption as a result of global warming. *Ambio*. 2020;49(4):865–880. doi: 10.1007/s13280-019-01234-6.
39. Cook O, Hildebrand M. Enhancing LC-PUFA production in *Thalassiosira pseudonana* by overexpressing the endogenous fatty acid elongase genes. *J Appl Phycol*. 2016;28(1):897–905. doi: 10.1007/s10811-015-0617-2.
40. Cordova LT, Alper HS. Production of α -linolenic acid in *Yarrowia lipolytica* using low-temperature fermentation. *Appl Microbiol Biotechnol*. 2018;102(20):8809–8816. doi: 10.1007/s00253-018-9349-y.
41. Correia M, Michel V, Matos AA, Carvalho P, Oliveira MJ, Ferreira RM, et al. Docosaehaenoic acid inhibits *Helicobacter pylori* growth in vitro and mice gastric mucosa colonization. *PLoS One*. 2012;7(4):e35072. doi: 10.1371/journal.pone.0035072.
42. Cui GZ, Ma Z, Liu YJ, Feng Y, Sun Z, Cheng Y, et al. Overexpression of glucose-6-phosphate dehydrogenase enhanced the polyunsaturated fatty acid composition of *Aurantiochytrium* sp. SD116. *Algal Res*. 2016;19:138–145. doi: 10.1016/j.algal.2016.08.005.
43. Dailey FE, McGraw JE, Jensen BJ, Bishop SS, Lokken JP, Dorff KJ, et al. The Microbiota of Freshwater Fish and Freshwater Niches Contain Omega-3 Fatty Acid-Producing *Shewanella* sp. *Appl Environ Microbiol*. 2015;82(1):218–231. doi: 10.1128/AEM.02266-15.
44. Das UN. Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: A review. *J Adv Res*. 2018;11:57–66. doi: 10.1016/j.jare.2018.01.001.
45. Chander M. *Rauwolfia serpentina*: A comprehensive phytochemical study of its bioactive metabolites. *Emerg Trends Metab*. 2024;1(2):14–40.
46. Chander M. Fungal-derived nutraceuticals & bioactive compounds with physiotherapeutic and health-promoting properties: A comprehensive review. *Int J Fungi*. 2025;2(2):1–9. doi: 10.37591/IJF.v02i02.228797.
47. Chander M, Paul M. Therapeutic & diagnostic applications of biosurfactants of microbial origin. *Int J Multidiscip Res*. 2025;7(1):1–25. doi: 10.36948/ijfmr.2025.v07i04.50288.
48. Chander M, Padda T. The Mycobiome Frontier – Pre & Post 2020 Status: Integrating Fungal Bioactive Compounds, Probiotics, and Antimicrobial Peptides in Modern Therapeutics and Biotechnology. *Int J Fungi*. 2026;3(1):19–29.
49. De Bhowmick G, Sarmah AK, Sen R. Zero-waste algal biorefinery for bioenergy and biochar: A green leap towards achieving energy and environmental sustainability. *Sci Total Environ*. 2019;650(2):2467–2482. doi: 10.1016/j.scitotenv.2018.10.002.
50. de Carvalho CCCR, Caramujo MJ. The Various Roles of Fatty Acids. *Molecules*. 2018;23(10):2583. doi: 10.3390/molecules23102583.
51. Desbois AP. Potential applications of antimicrobial fatty acids in medicine, agriculture and other industries. *Recent Pat Antiinfect Drug Discov*. 2012;7(2):111–122. doi: 10.2174/157489112801619728.
52. Desbois AP. Antimicrobial properties of eicosapentaenoic acid (C20:5, n–3). In: Kim SK, editor. *Marine Microbiology*. Wiley Online Library; 2013. p. 351–367.
53. Desbois AP, Lawlor KC. Antibacterial activity of long-chain polyunsaturated fatty acids against *Propionibacterium acnes* and *Staphylococcus aureus*. *Mar Drugs*. 2013;11(11):4544–4557. doi: 10.3390/md11114544.
54. Diao J, Song X, Guo T, Wang F, Chen L, Zhang W. Cellular engineering strategies toward sustainable omega-3 long chain polyunsaturated fatty acids production: State of the art and perspectives. *Biotechnol Adv*. 2020;40:107497. doi: 10.1016/j.biotechadv.2019.107497.
55. Di Nunzio M, Valli V, Bordoni A. Pro- and anti-oxidant effects of polyunsaturated fatty acid supplementation in HepG2 cells. *Prostaglandins Leukot Essent Fatty Acids*. 2011;85(3–4):121–127. doi: 10.1016/j.plefa.2011.07.005.
56. Djuricic I, Calder PC. Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021. *Nutrients*. 2021;13(7):2421. doi: 10.3390/nu13072421.

57. Domenichiello AF, Kitson AP, Bazinet RP. Is docosahexaenoic acid synthesis from α -linolenic acid sufficient to supply the adult brain? *Prog Lipid Res.* 2015;59:54–66. doi: 10.1016/j.plipres.2015.04.002.
58. Dourou M, Tsolcha ON, Tekerlekopoulou AG, Bokas D, Aggelis G. Fish farm effluents are suitable growth media for *Nannochloropsis gaditana*, a polyunsaturated fatty acid producing microalga. *Eng Life Sci.* 2018;18(11):851–860. doi: 10.1002/elsc.201800064.
59. Du F, Wang YZ, Xu YS, Shi TQ, Liu WZ, Sun XM, et al. Biotechnological production of lipid and terpenoid from *Thraustochytrids*. *Biotechnol Adv.* 2021;48:107725. doi: 10.1016/j.biotechadv.2021.107725.
60. Dyll SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. *Neuromol Med.* 2017;10(3):219–235.
61. Elagizi A, Lavie CJ, O’Keefe E, Marshall K, O’Keefe JH, Milani RV. An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health. *Nutrients.* 2021;13(1):204. doi: 10.3390/nu13010204.
62. Estupiñán M, Hernández I, Saitua E, Bilbao ME, Mendibil I, Ferrer J, et al. Novel *Vibrio* spp. Strains Producing Omega-3 Fatty Acids Isolated from Coastal Seawater. *Mar Drugs.* 2020;18(2):99. doi: 10.3390/md18020099.
63. Ethier S, Woisard K, Vaughan D, Wen Z. Continuous culture of the microalgae *Schizochytrium limacinum* on biodiesel-derived crude glycerol for producing docosahexaenoic acid. *Bioresour Technol.* 2011;102(1):88–93. doi: 10.1016/j.biortech.2010.05.021.
64. Faktorová D, Nisbet RER, Fernández Robledo JA, Casacuberta E, Sudek L, Allen AE, et al. Genetic tool development in marine protists: Emerging model organisms for experimental cell biology. *Nat Methods.* 2020;17(5):481–494. doi: 10.1038/s41592-020-0796-x.
65. Fang H, Zhao C, Chen S. Single cell oil production by *Mortierella isabellina* from steam exploded corn stover degraded by three-stage enzymatic hydrolysis in the context of on-site enzyme production. *Bioresour Technol.* 2016;216:988–995. doi: 10.1016/j.biortech.2016.06.051.
66. Ferenczi A, Pyott DE, Xipnitou A, Molnar A. Efficient targeted DNA editing and replacement in *Chlamydomonas reinhardtii* using Cpf1 ribonucleoproteins and single-stranded DNA. *Proc Natl Acad Sci U S A.* 2017;114(51):13567–13572. doi: 10.1073/pnas.1710597114.
67. Gadamchetty P, Mullapudi PLV, Sanagala R, Markandan M, Polumetla AK. Genetic transformation of *Chlorella vulgaris* mediated by HIV-TAT peptide. *3 Biotech.* 2019;9(4):139. doi: 10.1007/s13205-019-1671-2.
68. Gao W, Kim JY, Anderson JR, Akopian T, Hong S, Jin YY, et al. The cyclic peptide ecumicin targeting ClpC1 is active against *Mycobacterium tuberculosis* in vivo. *Antimicrob Agents Chemother.* 2015;59(2):880–889. doi: 10.1128/AAC.04054-14.
69. Gardeli C, Athenaki M, Xenopoulos E, Mallouchos A, Koutinas AA, Aggelis G, et al. Lipid production and characterization by *Mortierella (Umbelopsis) isabellina* cultivated on lignocellulosic sugars. *J Appl Microbiol.* 2017;123(6):1461–1477. doi: 10.1111/jam.13587.
70. Ge C, Chen H, Mei T, Tang X, Chang L, Gu Z, et al. Application of a ω -3 Desaturase with an Arachidonic Acid Preference to Eicosapentaenoic Acid Production in *Mortierella alpina*. *Front Bioeng Biotechnol.* 2018;5:313655. doi: 10.3389/fbioe.2017.00089.
71. Gemperlein K, Dietrich D, Kohlstedt M, Zipf G, Bernauer HS, Wittmann C, et al. Polyunsaturated fatty acid production by *Yarrowia lipolytica* employing designed myxobacterial PUFA synthases. *Nat Commun.* 2019;10(1):4055. doi: 10.1038/s41467-019-12025-8.
72. Gemperlein K, Rachid S, Garcia RO, Wenzel SC, Müller R. Polyunsaturated fatty acid biosynthesis in myxobacteria: Different PUFA synthases and their product diversity. *Chem Sci.* 2014;5(5):1733–1741. doi: 10.1039/C3SC53163E.
73. Gemperlein K, Zipf G, Bernauer HS, Müller R, Wenzel SC. Metabolic engineering of *Pseudomonas putida* for production of docosahexaenoic acid based on a myxobacterial PUFA synthase. *Metab Eng.* 2016;33:98–108. doi: 10.1016/j.ymben.2015.11.001.
74. Ghazani SM, Marangoni AG. Microbial lipids for foods. *Trends Food Sci Technol.* 2021;119:593–607. doi: 10.1016/j.tifs.2021.10.014.

75. Görner C, Redai V, Bracharz F, Schrepfer P, Garbe D, Brück T. Genetic engineering and production of modified fatty acids by the non-conventional oleaginous yeast *Trichosporon oleaginosus* ATCC 20509. *Green Chem.* 2016;18(7):2037–2046. doi: 10.1039/C5GC01767J.
76. Groenewald M, Boekhout T, Neuvéglise C, Gaillardin C, van Dijck PW, Wyss M. *Yarrowia lipolytica*: Safety assessment of an oleaginous yeast with a great industrial potential. *Crit Rev Microbiol.* 2014;40(3):187–206. doi: 10.3109/1040841X.2013.770386.
77. Gow RV, Hibbeln JR. Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. *Child Adolesc Psychiatr Clin N Am.* 2014;23(3):555–590. doi: 10.1016/j.chc.2014.02.002.
78. Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. *Cochrane Database Syst Rev.* 2015;(7):CD010085. doi: 10.1002/14651858.CD010085.pub2.
79. Guo M, Chen G, Chen J, Zheng M. Identification of a long-chain fatty acid elongase from *Nannochloropsis* sp. involved in the biosynthesis of fatty acids by heterologous expression in *Saccharomyces cerevisiae*. *J Ocean Univ China.* 2019;18(5):1199–1206. doi: 10.1007/s11802-019-3946-y.
80. Guo P, Dong L, Wang F, Chen L, Zhang W. Deciphering and engineering the polyunsaturated fatty acid synthase pathway from eukaryotic microorganisms. *Front Bioeng Biotechnol.* 2022;10:1052785. doi: 10.3389/fbioe.2022.1052785.
81. Gupta A, Abraham RE, Barrow CJ, Puri M. Omega-3 fatty acid production from enzyme saccharified hemp hydrolysate using a novel marine thraustochytrid strain. *Bioresour Technol.* 2015;184:373–378. doi: 10.1016/j.biortech.2014.11.031.
82. Gupta A, Barrow CJ, Puri M. Omega-3 biotechnology: Thraustochytrids as a novel source of omega-3 oils. *Biotechnol Adv.* 2012;30(6):1733–1745. doi: 10.1016/j.biotechadv.2012.02.014.
83. Hamilton ML, Powers S, Napier JA, Sayanova O. Heterotrophic production of omega-3 long-chain polyunsaturated fatty acids by trophically converted marine diatom *Phaeodactylum tricornutum*. *Mar Drugs.* 2016;14(3):53. doi: 10.3390/md14030053.
84. Han X, Zhao Z, Wen Y, Chen Z. Enhancement of docosahexaenoic acid production by overexpression of ATP-citrate lyase and acetyl-CoA carboxylase in *Schizochytrium* sp. *Biotechnol Biofuels.* 2020;13:131. doi: 10.1186/s13068-020-01767-z.
85. Hernández-Ramírez J, Wong-Arce A, González-Ortega O, Rosales-Mendoza S. Expression in algae of a chimeric protein carrying several epitopes from tumor associated antigens. *Int J Biol Macromol.* 2020;147:46–52. doi: 10.1016/j.ijbiomac.2019.12.250.
86. Hildebrand M, Manandhar-Shrestha K, Abbriano R. Effects of chrysolaminarin synthase knockdown in the diatom *Thalassiosira pseudonana*: Implications of reduced carbohydrate storage relative to green algae. *Algal Res.* 2017;23:66–77. doi: 10.1016/j.algal.2017.01.010.
87. Hopes A, Nekrasov V, Kamoun S, Mock T. Editing of the urease gene by CRISPR-Cas in the diatom *Thalassiosira pseudonana*. *Plant Methods.* 2016;12:49. doi: 10.1186/s13007-016-0148-0.
88. Huang CB, Ebersole JL. A novel bioactivity of omega-3 polyunsaturated fatty acids and their ester derivatives. *Mol Oral Microbiol.* 2010;25(1):75–80. doi: 10.1111/j.2041-1014.2009.00553.x.
89. Huang TH, Wang PW, Yang SC, Chou WL, Fang JY. Cosmetic and therapeutic applications of fish oil's fatty acids on the skin. *Mar Drugs.* 2018;16(8):256.
90. Huang W, Daboussi F. Genetic and metabolic engineering in diatoms. *Philos Trans R Soc Lond B Biol Sci.* 2017;372(1728):20160411.
91. Iwasaka H, Aki T, Adachi H, Watanabe K, Kawamoto S, Ono K. Utilization of waste syrup for production of polyunsaturated fatty acids and xanthophylls by *Aurantiochytrium*. *J Oleo Sci.* 2013;62(9):729–736. doi: 10.5650/jos.62.729.
92. Jackman JA, Yoon BK, Li D, Cho NJ. Nanotechnology formulations for antibacterial free fatty acids and monoglycerides. *Molecules.* 2016;21(3):305. doi: 10.3390/molecules21030305.
93. Jain T. Fatty acid composition of oilseed crops: A review. In: Singh J, Kumar D, Kumar P, editors. *Oilseed Crops*. Cham: Springer; 2020. p.147–153.

94. Jiang WZ, Weeks DP. A gene-within-a-gene Cas9/sgRNA hybrid construct enables gene editing and gene replacement strategies in *Chlamydomonas reinhardtii*. *Algal Res.* 2017;26:474–480. doi: 10.1016/j.algal.2017.04.001.
95. Jiang W, Brueggeman AJ, Horken KM, Plucinak TM, Weeks DP. Successful transient expression of Cas9 and single guide RNA genes in *Chlamydomonas reinhardtii*. *Eukaryot Cell.* 2014;13(11):1465–1469. doi: 10.1128/EC.00213-14.
96. Jia YL, Wang LR, Zhang ZX, Gu Y, Sun XM. Recent advances in biotechnological production of polyunsaturated fatty acids by *Yarrowia lipolytica*. *Crit Rev Food Sci Nutr.* 2022;62(32):8920–8934. doi: 10.1080/10408398.2021.1937041.
97. Ji XJ, Huang H. Engineering microbes to produce polyunsaturated fatty acids. *Trends Biotechnol.* 2019;37(4):344–346. doi: 10.1016/j.tibtech.2018.10.002.
98. Johansson M, Chen X, Milanova S, Santos C, Petranovic D. PUFA-induced cell death is mediated by Yca1p-dependent and -independent pathways, and is reduced by vitamin C in yeast. *FEMS Yeast Res.* 2016;16(2):fow007. doi: 10.1093/femsyr/fow007.
99. Jones AD, Boundy-Mills KL, Barla GF, Kumar S, Ubanwa B, Balan V. Microbial lipid alternatives to plant lipids. In: *Lipids and Lipid Polymers in Biotechnology*. New York (NY): Humana; 2019. p.1–32.
100. Jovanovic S, Dietrich D, Becker J, Kohlstedt M, Wittmann C. Microbial production of polyunsaturated fatty acids, high-value ingredients for aquafeed, superfoods, and pharmaceuticals. *Curr Opin Biotechnol.* 2021;69:199–211. doi: 10.1016/j.copbio.2021.01.009.
101. Jung SW, Lee SW. The antibacterial effect of fatty acids on *Helicobacter pylori* infection. *Korean J Intern Med.* 2016;31(1):30–35. doi: 10.3904/kjim.2016.31.1.30.
102. Kang S, Jeon S, Kim S, Chang YK, Kim YC. Development of a pVEC peptide-based ribonucleoprotein (RNP) delivery system for genome editing using CRISPR/Cas9 in *Chlamydomonas reinhardtii*. *Sci Rep.* 2020;10(1):22158. doi: 10.1038/s41598-020-78968-x.
103. Kannan N, Rao AS, Nair A. Microbial production of omega-3 fatty acids: An overview. *J Appl Microbiol.* 2021;131(5):2114–2130. doi: 10.1111/jam.15034.
104. Karas BJ, Diner RE, Lefebvre SC, McQuaid J, Phillips AP, Noddings CM, et al. Designer diatom episomes delivered by bacterial conjugation. *Nat Commun.* 2015;6:6925. doi: 10.1038/ncomms7925.
105. Karamerou EE, Parsons S, McManus MC, Chuck CJ. Using techno-economic modelling to determine the minimum cost possible for a microbial palm oil substitute. *Biotechnol Biofuels.* 2021;14(1):57. doi: 10.1186/s13068-021-01911-3.
106. Katsuyama Y. Mining novel biosynthetic machineries of secondary metabolites from actinobacteria. *Biosci Biotechnol Biochem.* 2019;83(9):1606–1615. doi: 10.1080/09168451.2019.1606700.
107. Ken S, Robert SC, Steven AL. Docosahexaenoic acid. *Curr Alzheimer Res.* 2016;13(2):173–18.
108. Khan AW, Chun-Mei H, Khan N, Iqbal A, Lyu SW, Shah F. Bioengineered plants can be a useful source of omega-3 fatty acids. *Biomed Res Int.* 2017;2017:7348919. doi: 10.1155/2017/7348919.
109. Kikukawa H, Sakuradani E, Ando A, Shimizu S, Ogawa J. Arachidonic acid production by the oleaginous fungus *Mortierella alpina* 1S-4: A review. *J Adv Res.* 2018;11:15–22. doi: 10.1016/j.jare.2018.02.003.
110. Kim GC, Cheon DH, Lee Y. Challenge to overcome current limitations of cell-penetrating peptides. *Biochim Biophys Acta Proteins Proteom.* 2021;1869(4):140604. doi: 10.1016/j.bbapap.2021.140604.
111. Kobayashi T, Sakaguchi K, Matsuda T, Abe E, Hama Y, Hayashi M, et al. Increase of eicosapentaenoic acid in thraustochytrids through thraustochytrid ubiquitin promoter-driven expression of a fatty acid $\Delta 5$ desaturase gene. *Appl Environ Microbiol.* 2011;77(11):3870–3876. doi: 10.1128/AEM.02664-10.
112. Köfeler HC, Fauland A, Rechberger GN, Trötz Müller M. Mass spectrometry based lipidomics: An overview of technological platforms. *Metabolites.* 2012;2(1):19–38. doi: 10.3390/metabo2010019.

113. Kotnik T, Frey W, Sack M, Haberl Meglič S, Peterka M, Miklavčič D. Electroporation-based applications in biotechnology. *Trends Biotechnol.* 2015;33(8):480–488. doi: 10.1016/j.tibtech.2015.06.002.
114. Kumar P, Nagarajan A, Uchil PD. Electroporation. *Cold Spring Harb Protoc.* 2019;2019(7):pdb.top096271. doi: 10.1101/pdb.top096271.
115. Kumar R, Salwan R, Sharma N, Singh A, Kumari D, Singh R, et al. Anticancer potential and other therapeutic activities of curcumin & its derivatives. *Emerg Trends Metab.* 2026;3(1):19–28. doi: 10.37591/ETM.v03i01.239102.
116. Liang Y, Liu Y, Tang J, Ma J, Cheng JJ, Daroch M. Transcriptomic profiling and gene disruption revealed that two genes related to PUFAs/DHA biosynthesis may be essential for cell growth of *Aurantiochytrium* sp. *Mar Drugs.* 2018;16(9):310. doi: 10.3390/md16090310.
117. Lopes da Silva T, Moniz P, Silva C, Reis A. The dark side of microalgae biotechnology: A heterotrophic biorefinery platform directed to ω -3 rich lipid production. *Microorganisms.* 2019;7(12):670. doi: 10.3390/microorganisms7120670.
118. Malibari R, Sayegh F, Elazzazy AM, Baeshen MN, Dourou M, Aggelis G. Reuse of shrimp farm wastewater as growth medium for marine microalgae isolated from Red Sea–Jeddah. *J Clean Prod.* 2018;198:160–169.
119. Masurkar AAK, Datar AG, Vakil BV. New microbial sources of PUFA from the Arabian sea and fresh water habitats of Indian territory. *Int J Pharm Sci.* 2014;6(1):349–360. doi: 10.13040/IJPSR.0975-8232.6(1).349–60.
120. Mattos GN, Tonon RV, Furtado AA, Cabral LM. Grape by-product extracts against microbial proliferation and lipid oxidation: A review. *J Sci Food Agric.* 2017;97(4):1055–1064. doi: 10.1002/jsfa.8062.
121. Metherel AH, Armstrong JM, Patterson AC, Stark KD. Assessment of blood measures of n-3 polyunsaturated fatty acids with acute fish oil supplementation and washout in men and women. *Prostaglandins Leukot Essent Fatty Acids.* 2009;81(1):23–29. doi: 10.1016/j.plefa.2009.05.018.
122. Mhlongo SI, Ezeokoli OT, Roopnarain A, Ndaba B, Sekoai PT, Habimana O, et al. The potential of single-cell oils derived from filamentous fungi as alternative feedstock sources for biodiesel production. *Front Microbiol.* 2021;12:637381. doi: 10.3389/fmicb.2021.637381.
123. Mileski KS, Ćirić AD, Trifunović SS, Ristić MS, Soković MD, Matevski VS, et al. *Heracleum orphanidis*: Chemical characterisation, and comparative evaluation of antioxidant and antimicrobial activities with specific interest in the influence on *Pseudomonas aeruginosa* PAO1. *Food Funct.* 2016;7(9):4061–4074. doi: 10.1039/c6fo01018k.
124. Miranda C, Bettencourt S, Pozdniakova T, Pereira J, Sampaio P, Franco-Duarte R, et al. Modified high-throughput Nile red fluorescence assay for the rapid screening of oleaginous yeasts using acetic acid as carbon source. *BMC Microbiol.* 2020;20(1):60. doi: 10.1186/s12866-020-01742-6.
125. Mhlongo SI, Ezeokoli OT, Roopnarain A, Ndaba B, Sekoai PT, Habimana O, et al. The potential of single-cell oils derived from filamentous fungi as alternative feedstock sources for biodiesel production. *Front Microbiol.* 2021;12:637381. doi: 10.3389/fmicb.2021.637381.
126. Mohamed H, Naz T, Yang J, Shah AM, Nazir Y, Song Y. Recent molecular tools for the genetic manipulation of highly industrially important Mucoromycota fungi. *J Fungi (Basel).* 2021;7(12):1061. doi: 10.3390/jof7121061.
127. Moss JW, Ramji DP. Nutraceutical therapies for atherosclerosis. *Nat Rev Cardiol.* 2016;13(9):513–532. doi: 10.1038/nrcardio.2016.103.
128. Moustogianni A, Bellou S, Triantaphyllidou IE, Aggelis G. Feasibility of raw glycerol conversion into single cell oil by zygomycetes under non-aseptic conditions. *Biotechnol Bioeng.* 2015;112(4):827–831. doi: 10.1002/bit.25482.
129. Muñoz CF, de Jaeger L, Sturme MHJ, Lip KYF, Olijslager JWJ, Springer J, et al. Improved DNA/protein delivery in microalgae, a simple and reliable method for the prediction of optimal electroporation settings. *Algal Res.* 2018;33:448–455.
130. Oliver L, Dietrich T, Marañón I, Villarán MC, Barrio RJ. Producing omega-3 polyunsaturated fatty acids: A review of sustainable sources and future trends for the EPA and DHA market. *Resources.* 2020;9(12):148. doi: 10.3390/resources9120148.

131. Qin J, Kurt E, LBassi T, Sa L, Xie D. Biotechnological production of omega-3 fatty acids: Current status and future perspectives. *Front Microbiol.* 2023;14. doi: 10.3389/fmicb.2023.1280296.
132. Rampal P, Chander M. Plant bioactive metabolites and their role in the prevention and control of dental diseases and infections. *Emerg Trends Metab.* 2026;3(1):47–66. doi: 10.37591/ETM.v03i01.239648.
133. Singh S, Kapoor S, Chander M, Gill PK. Recent update on serum alkaline and acid phosphatases in pre- and postoperative breast cancer patients. *Sudan J Med Sci.* 2022;17(1). doi: 10.18502/sjms.v17i1.10686.
134. Saini RK, Prasad P, Sreedhar RV, Akhilender Naidu K, Shang X, Keum YS. Omega-3 polyunsaturated fatty acids (PUFAs): Emerging plant and microbial sources, oxidative stability, bioavailability, and health benefits: A review. *Antioxidants (Basel).* 2021;10(10):1627. doi: 10.3390/antiox10101627.
135. Silva D, Villarroel MP, Roa AL, Quilodr n BH. Use of waste from agroindustrial sources as substrate for polyunsaturated fatty acids production by *Thraustochytrium Kinney VAL-B1*. *Int J Eng Res Afr.* 2017;33:50–55. doi: 10.4028/www.scientific.net/JERA.33.50.
136. Song Z, Stajich JE, Xie Y, Liu X, He Y, Chen J, et al. Comparative analysis reveals unexpected genome features of newly isolated thraustochytrids strains: On ecological function and PUFAs biosynthesis. *BMC Genomics.* 2018;19(1):541. doi: 10.1186/s12864-018-4904-6.
137. Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the bloodstream of healthy adults. *Prog Lipid Res.* 2016;63:132–152. doi: 10.1016/j.plipres.2016.05.001.
138. Sun M, Zhou Z, Dong J, Zhang J, Xia Y, Shu R. Antibacterial and antibiofilm activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against periodontopathic bacteria. *Microb Pathog.* 2016;99:196–203. doi: 10.1016/j.micpath.2016.08.025.
139. Tanaka T, Yabuuchi T, Maeda Y, Nojima D, Matsumoto M, Yoshino T. Production of eicosapentaenoic acid by high cell density cultivation of the marine oleaginous diatom *Fistulifera solaris*. *Bioresour Technol.* 2017;245(Pt A):567–572. doi: 10.1016/j.biortech.2017.09.005.
140. Yin FW, Zhu SY, Guo DS, Ren LJ, Ji XJ, Huang H, et al. Development of a strategy for the production of docosahexaenoic acid by *Schizochytrium* sp. from cane molasses and algae-residue. *Bioresour Technol.* 2019;271:118–124. doi: 10.1016/j.biortech.2018.09.114.
141. Yu XJ, Wang ZP, Liang MJ, Wang Z, Liu XY, Hu L, et al. One-step utilization of inulin for docosahexaenoic acid (DHA) production by recombinant *Aurantiochytrium* sp. carrying *Kluyveromyces marxianus* inulinase. *Bioprocess Biosyst Eng.* 2020;43(10):1801–1811. doi: 10.1007/s00449-020-02371-z.
142. Zhang J, Burgess JG. Enhanced eicosapentaenoic acid production by a new deep-sea marine bacterium *Shewanella electrodiphila* MAR441T. *PLoS One.* 2017;12(11):e0188081. doi: 10.1371/journal.pone.0188081.
143. Zhang S, He Y, Sen B, Chen X, Xie Y, Keasling JD, et al. Alleviation of reactive oxygen species enhances PUFA accumulation in *Schizochytrium* sp. through regulating genes involved in lipid metabolism. *Metab Eng Commun.* 2018;6:39–48. doi: 10.1016/j.meteno.2018.03.002.
144. Zhao P, Yu X, Li J, Tang X, Huang Z. Enhancing lipid productivity by co-cultivation of *Chlorella* sp. U4341 and *Monoraphidium* sp. FXY-10. *J Biosci Bioeng.* 2014;118(1):72–77. doi: 10.1016/j.jbiosc.2013.12.014.
145. Zivkovic AM, Telis N, German JB, Hammock BD. Dietary omega-3 fatty acids aid in the modulation of inflammation and metabolic health. *Calif Agric.* 2011;65(3):106–111. doi: 10.3733/ca.v065n03p106.
146. Zou LG, Chen JW, Zheng DL, Balamurugan S, Li DW, Yang WD, et al. High-efficiency promoter-driven coordinated regulation of multiple metabolic nodes elevates lipid accumulation in the model microalga *Phaeodactylum tricornutum*. *Microb Cell Fact.* 2018;17(1):54. doi: 10.1186/s12934-018-0906-y.